NCT06299436 Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
| NCT ID | NCT06299436 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Heart Failure With Reduced Ejection Fraction |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-12-10 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-12-10 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.
Eligibility Criteria
Inclusion Criteria: * Adult patients aged between 18 and 90 years of age * Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%) * Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure Exclusion Criteria: * Unable to interrupt VKA anticoagulation * Point of care International Normalized Ratio (INR) \> 1.5 * Pregnant patients * Acute hospitalization or decompensation within 2 weeks prior to study date * Participation in a study involving an investigational drug within 4 weeks prior to study date * Inability to lie flat in the supine position * Symptomatic hemodynamic instability at rest or during the procedure
Contact & Investigator
Steven Hsu, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins School of Medicine
Frequently Asked Questions
Who can join the NCT06299436 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Heart Failure With Reduced Ejection Fraction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06299436 currently recruiting?
Yes, NCT06299436 is actively recruiting participants. Contact the research team at steven.hsu@jhmi.edu for enrollment information.
Where is the NCT06299436 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06299436 clinical trial?
NCT06299436 is sponsored by Johns Hopkins University. The principal investigator is Steven Hsu, MD at Johns Hopkins School of Medicine. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.